Fig. 4From: 18F-FDG PET/CT based spleen to liver ratio associates with clinical outcome to ipilimumab in patients with metastatic melanomaSLR and overall survival after ipilimumab in the validation cohort. High SLR was associated with poor overall survival after ipilimumab treatment. This was validated in an external cohort (n = 110 patients) from Brussels and Zurich (median 2.3 months versus 11.9 months, HR 3.74, CI 1.34–10.4)Back to article page